Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	30.49B -32.6%
Revenue (ttm)	6.85B -15.7%
Net Income	1.33B -33.7%
EPS	0.20 -32.8%
Shares Out	6.56B
PE Ratio	22.98
Forward PE	16.61
Dividend	0.05 (1.04%)
Ex-Dividend Date	Feb 10, 2026

Volume	50,155,785
Open	4.890
Previous Close	4.690
Day's Range	4.640 - 4.890
52-Week Range	4.640 - 7.260
Beta	0.31
Analysts	Strong Buy
Price Target	6.00 (+29.03%)
Earnings Date	Aug 28, 2026

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product. It also provides specific immune, human tetanus immunoglobulin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 4,045
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2025, SHE:002252's revenue was 7.35 billion, a decrease of -10.13% compared to the previous year's 8.18 billion. Earnings were 1.58 billion, a decrease of -28.10%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error